海思科(002653.SZ)：创新药HSK39297片纳入突破性治疗药物程序

智通财经10-13

智通财经APP讯，海思科(002653.SZ)发布公告，公司于2025年10月13日获悉，HSK39297片正式被国家药品监督管理局药品审评中心(CDE)纳入《突破性治疗品种名单》，将极大的推动该领域新药的研发历程，为我国肾脏/泌尿系统疾病的治疗带来新的希望。HSK39297是公司自主研发的一种口服、强效和高选择性的补体因子B小分子抑制剂。临床拟用于治疗补体参与介导的溶血性疾病及补体参与介导的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2575478792?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-13 15:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575478792","market":"fut","top_or_hot":-1,"title":"海思科(002653.SZ)：创新药HSK39297片纳入突破性治疗药物程序","media":"智通财经","content":"<div>\n<p>智通财经APP讯， 海思科(002653.SZ)发布公告，公司于2025年10月13日获悉，HSK39297片正式被国家药品监督管理局药品审评中心(CDE)纳入《突破性治疗品种名单》，将极大的推动该领域新药的研发历程，为我国肾脏/泌尿系统疾病的治疗带来新的希望。HSK39297是公司自主研发的一种口服、强效和高选择性的补体因子B小分子抑制剂。临床拟用于治疗补体参与介导的溶血性疾病及补体参与介导的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1354211.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>海思科(002653.SZ)：创新药HSK39297片纳入突破性治疗药物程序</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n海思科(002653.SZ)：创新药HSK39297片纳入突破性治疗药物程序\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-13 15:56 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1354211.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯， 海思科(002653.SZ)发布公告，公司于2025年10月13日获悉，HSK39297片正式被国家药品监督管理局药品审评中心(CDE)纳入《突破性治疗品种名单》，将极大的推动该领域新药的研发历程，为我国肾脏/泌尿系统疾病的治疗带来新的希望。HSK39297是公司自主研发的一种口服、强效和高选择性的补体因子B小分子抑制剂。临床拟用于治疗补体参与介导的溶血性疾病及补体参与介导的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1354211.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0033","symbol_name":"西藏振兴","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1354211.html","article_id":"2575478792","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575478792","pubTimestamp":1760342183,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"HSK39297是公司自主研发的一种口服、强效和高选择性的补体因子B小分子抑制剂。目前HSK39297片在原发性IgA肾病患者中开展Ⅱ期临床研究中并完成了12周的核心治疗期，临床结果显示达到预设终点。HSK39297片连续治疗12周能够较安慰剂组显著降低尿蛋白水平，整体安全性和耐受性良好，为其纳入突破性治疗品种及进入Ⅲ期关键性临床研究阶段奠定了坚实的基础。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","BK0033":"西藏振兴","BK0077":"质押式回购","BK0239":"医药制造","06978":"永泰生物-B","BK0028":"国家队","002653":"海思科","BK0188":"融资融券","BK1574":"生物医药B类股","BK1161":"生物科技"},"translate_title":"Haisco (002653. SZ): The innovative drug HSK39297 tablets are included in the breakthrough therapeutic drug program","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1.5,"002653":1.5,"06978":1.5},"content_text":"智通财经APP讯， 海思科(002653.SZ)发布公告，公司于2025年10月13日获悉，HSK39297片正式被国家药品监督管理局药品审评中心(CDE)纳入《突破性治疗品种名单》，将极大的推动该领域新药的研发历程，为我国肾脏/泌尿系统疾病的治疗带来新的希望。HSK39297是公司自主研发的一种口服、强效和高选择性的补体因子B小分子抑制剂。临床拟用于治疗补体参与介导的溶血性疾病及补体参与介导的原发性或继发性肾小球疾病等。目前HSK39297片在原发性IgA肾病患者中开展Ⅱ期临床研究中并完成了12周的核心治疗期，临床结果显示达到预设终点。HSK39297片连续治疗12周能够较安慰剂组显著降低尿蛋白水平，整体安全性和耐受性良好，为其纳入突破性治疗品种及进入Ⅲ期关键性临床研究阶段奠定了坚实的基础。与此同时，公司正在推进HSK39297片针对阵发性睡眠性血红蛋白尿症的Ⅲ期临床研究。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2575478792","isCrawlerRequest":true}